Question and Answers
Question and Answers
Q. Who is responsible for reporting the final blood product disposition when units are issued to Ornge?
A. When a blood/blood product is issued to Ornge, Ornge is responsible for documenting any transfusions that occur en route to the receiving hospital on the Ornge Patient Call Report. The transfusion information on this Patient Call Report will be copied in the patient's chart becoming part of the receiving hospital's records. The receiving facility is responsible for reporting the final blood product disposition. If the sending facility is aware of the name of the receiving facility, the sending facility should notify the receiving facility's transfusion service that blood is being transferred with a patient via Ornge. Units not transfused are to be documented as "received from another facility" and either accepted into the receiving hospital's inventory or discarded depending on the receiving hospital's policies and/or the condition of the transferred units.
Q. Who should the hospital transfusion medicine services contact at Ornge if they need blood product final disposition information or if there is any other information needed regarding blood issued to or received via Ornge?
A. The contact at Ornge is as follows: Flo Veel, Patient Data Coordinator, Performance and Information Management Email address- Cette adresse e-mail est protégée contre les robots des spammeurs, vous devez activer Javascript pour la voir. Direct Phone- 647-428-2140.
Q. What is the total volume of red cells in a unit of packed red cells?
A. 160 mL; The red cells are concentrated by centrifugation and supernatant anticoagulated platelet-rich plasma removed. The resulting product has a volume of about 280 ml with red cells forming 50-60%.
Q. Since Canadian Blood Services (CBS) began using "male" only plasma is TRALI still considered a risk of plasma or platelet transfusions?
A. The use of "male only" plasma for frozen plasma and platelet preparations is expected to reduce substantially the frequency of TRALI; this has been the experience in other jurisdictions. The rationale is to remove from the supply plasma from women who may have been immunized in pregnancy against HLA and other leucocyte-borne antigens. However, this measure will not alone eliminate TRALI, as a proportion of cases involve a different, ill-understood, mechanism. Furthermore, it is unlikely that female donors can be removed from the red cell donor pool, and since TRALI is also mediated by the plasma in the red cell units, a small number of cases mediated by female plasma will likely remain. For further information and references see the recent review by Vamvakas and Blajchman, published on-line on 4/02/09 at www.bloodjournal.org.
Q. In Bloody Easy Online Program Module 1, Question 24. A 28-year-old G1P0 has just given birth to a 7lbs girl at 38 weeks gestation. The baby is noted to have some bruising and petechiae. Prenatal course was unremarkable. Ultrasound at 18 weeks was entirely normal. Maternal CBS after delivery shows Hb 100, WBC 11 and platelet 288. CBC from baby reveals Hb 200,WBC 11 and platelet 10. What is the best choice of platelet product for the baby until a definitive diagnosis can be made? Are antibodies not from mom so best answer would be HLA crossmatched platelets as would the mom's antibodies be present in any platelet concentrate. Is it due to no diagnosis made and time is urgent due to platelet count in newborn?
A. Transfuse maternal platelets to the baby. The rationale is that this thrombocytopenia is likely due to maternal antibodies to a paternal platelet antigen on the infants platelets. The quickest reliable source of compatible platelets is the mother, whose platelets will not be affected by antibody to the antigen derived from the fathers genetic constitution.
Q. The definitive routine laboratory test for diagnosis of the sickling syndromes is? Is sickledex not a screening test only? I realize it detects Hb S but does not detect Hb C/B Thalassemia etc.
A. Hemoglobin electrophoreis; Hb electrophoresis as usually done does not absolutely identify Hb S as other hemoglobins have the same electrophoretic mobility. The sickledex merely establishes the presence of Hb S without giving information on the proportion of Hb S or on the presence of other variants thus, you need both for definitive diagnosis. These tests are now being replaced with more sophisticated methods for identifying and quantifying abnormal hemoglobins.
Q. Positive DAT is not usually a feature of the hyperhemolysis syndrome associated with transfusion of sickle cell disease patients. A positive DAT is a feature of SS disease-course states not only do SS patients have elevated number of allo-antibodies especially Fya / Fyb but half have allo-antibodies especially to Kell, -E,-C and KIDD antigen stimulation. Do they not also have auto-antibodies as their own RBC's are more easily or rapidly destroyed in the spleen post-transfusion?
A. Hyperhemolysis is uncommon but dangerous. It does not appear to be immune mediated so a positive antiglobulin test would not be found unless the patient was also one of the minority (about 10%) who have a positive DAT test. However, even if that were the case, it would not likely be relevant to the hyperhemolytic process. The mechanism of hemolysis in S/S disease is mechanically, not immunilogically, mediated.
Q. The module course notes say that leukoreduction provides no benefit? Does it predispose patients to febrile reactions and platelet refactoriness?
A. Please refer to module 1, screen 13. It is the whites cells in routine blood donations that provide no benefits and have practical and theoretical adverse effects, not leukoreduction.
